News articles about Evolent Health (NYSE:EVH) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Evolent Health earned a coverage optimism score of 0.24 on Accern’s scale. Accern also assigned media coverage about the technology company an impact score of 47.6805450894185 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
EVH stock remained flat at $$15.00 during mid-day trading on Friday. The company’s stock had a trading volume of 823,689 shares, compared to its average volume of 626,544. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 0.12. Evolent Health has a 1-year low of $10.30 and a 1-year high of $27.50.
Evolent Health (NYSE:EVH) last issued its earnings results on Tuesday, February 27th. The technology company reported ($0.10) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.10). The business had revenue of $113.97 million during the quarter, compared to the consensus estimate of $111.09 million. Evolent Health had a negative return on equity of 3.51% and a negative net margin of 14.05%. research analysts anticipate that Evolent Health will post -0.34 earnings per share for the current year.
A number of equities analysts have recently issued reports on EVH shares. Canaccord Genuity lowered their price objective on Evolent Health from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday, February 28th. Jefferies Group set a $22.00 price objective on Evolent Health and gave the stock a “buy” rating in a research report on Tuesday, February 13th. Citigroup started coverage on Evolent Health in a research report on Thursday, January 4th. They set a “buy” rating for the company. Wells Fargo lowered their price objective on Evolent Health from $27.00 to $20.00 and set an “outperform” rating for the company in a research report on Wednesday, February 28th. Finally, Zacks Investment Research downgraded Evolent Health from a “hold” rating to a “sell” rating in a research report on Thursday, March 8th. Three investment analysts have rated the stock with a sell rating and twelve have issued a buy rating to the company. Evolent Health presently has an average rating of “Buy” and a consensus price target of $25.33.
In other Evolent Health news, Director Unitedhealth Group Inc sold 3,040,000 shares of Evolent Health stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $13.70, for a total value of $41,648,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 8.79% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/08/evolent-health-evh-given-daily-media-impact-rating-of-0-24.html.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.